Navigation Links
GenVec Reports Fourth Quarter and 2011 Year-End Financial Results
Date:3/15/2012

ts associated with both our internal research programs and funded programs. General and administrative expenses in the fourth quarter of 2011 increased 33% to $2.0 million from $1.5 million in the comparable period in 2010 primarily due to increased personnel and recruiting costs, partially offset by lower professional costs.

2012 GuidanceGenVec's Senior Vice President and Chief Financial Officer, Douglas J. Swirsky, commented, "For 2012, we anticipate our cash burn will average $2.0 million per quarter."

Conference Call Information GenVec will hold a conference call today at 10:00 a.m. EDT to discuss the Company's financial results and 2012 business outlook. To listen to the live conference call, please dial 877-558-0567 (U.S. or Canada) or 706-643-4980 (international) and use the following Conference ID: 47684520. An audio replay of the conference call will be available starting at 1:00 p.m. EDT on March 15, 2012 through March 22, 2012. To listen to the audio replay, dial 855-859-2056 or 404-537-3406 (international) and use access code 47684520.

A live webcast of the conference call will be available on the Company's website and will be archived for 30 days. To access the webcast or the replay, go to www.genvec.com, and click on "Investors and Media".

About GenVecGenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infecti
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. GenVec President and Chief Executive Officer Announces Retirement
2. GenVec Achieves Second Milestone in Collaboration
3. GenVec to Present at the 2011 10th Annual BIO Investor Forum
4. GenVec Renews Stockholder Rights Plan
5. GenVec Reports First Quarter 2011 Financial Results
6. GenVec Regains Compliance with NASDAQ Listing Requirements
7. GenVec, Inc. Announces Effectiveness of Reverse Stock Split
8. GenVec To Host Fourth Quarter and Year-End 2010 Earnings Call and Webcast
9. GenVec to Present at the 13th Annual BIO CEO & Investor Conference
10. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
11. GenVec Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015   GenoSpace , a ... interpretation and analysis of genomic and other biomedical ... has joined the company as Vice President of ... http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace partners with ... interpret, analyze and explore complex sets of genomic, ...
(Date:7/30/2015)... ... ... The 2015 Market Research Report on the Global Propanol Industry ... market with a focus on the Chinese situation. Major companies included in the propanol ... Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report provides ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading ... clinical study of its canine osteoarthritis stem cell product, currently under development for ... KS) and will be marketed in the US by Aratana. This product, termed ...
(Date:7/30/2015)... , Inc. (NASDAQ: SNMX ), a leading company ... commercialize novel flavor ingredients for the food, beverage, and ... second quarter 2015. "Moving into the ... achieve our commercial and financial goals," stated John Poyhonen, ... our last quarterly earnings report, our two partners have ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
... BIOFUEL ENERGY CORP. (Nasdaq: BIOF ... 2010 results.  For the quarter ended September 30, 2010, revenues ... million, compared to revenues of $91.1 million and a net ...  Net loss attributable to common shareholders was $1.4 million, or ...
... can wear on your nerves, but it really does ... in automotive fuel cells. Before large fleets of fuel-cell-powered ... find a way to protect the platinum, the most ... amount needed to make catalytically active electrodes. Now, ...
... Corporation (Nasdaq: DNDN ) today announced ... post-approval supplement to the PROVENGE® (sipuleucel-T) Biologics License ... facility. Dendreon is requesting licensure for an additional ... Food and Drug Administration (FDA) review for a ...
Cached Biology Technology:BioFuel Energy Reports Third Quarter Results 2BioFuel Energy Reports Third Quarter Results 3BioFuel Energy Reports Third Quarter Results 4BioFuel Energy Reports Third Quarter Results 5New highly stable fuel-cell catalyst gets strength from its nano core 2New highly stable fuel-cell catalyst gets strength from its nano core 3Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility 2
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
(Date:7/7/2015)... Research and Markets ... the "Capacitive Fingerprint Sensors Patent Landscape" ... date, fingerprint sensing technology is the most reliable ... well developed. This patent landscape focuses on fingerprint ... domain of capacitive fingerprint sensors is closely linked ...
(Date:7/7/2015)... Conn. , July 7, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market announces a revised version ... this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the cards ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... deciphered the structure of an essential part of Mediator, a ... the transcription of DNA. The research adds an important ... deeper understanding of how cells translate genetic information into the ... July 3 advance online issue of the journal Nature ...
... have specially adapted self-cleaning feet which could have practical ... may provide a design for self-cleaning sticky surfaces, which ... especially in contaminating environments - medical bandages, tyre performance, ... at the University of Glasgow who will be presenting ...
... The question of why there are so many species in ... in marine biology. Below the waterline, about 30% of Hawai,i,s marine ... else on Earth one of the highest rates of endemism ... from? Hawai,i is famous for its adaptive radiations (the formation ...
Cached Biology News:Researchers decipher protein structure of key molecule in DNA transcription system 2Frog feet could solve a sticky problem 2Scientists discover that Hawai'i is not an evolutionary dead end for marine life 2
Miscellaneous: Versatile stain for staining RNA (bluish-purple), DNA (blue), proteins (red) and acid polysaccharides Assay: ~ 95 % Suitab tst: differential staining of nucleic acids and prote...
Screening test for the detection of Salmonella sp. by means of DNA amplification, subsequent molecular hybridization and detection on a microtitre plate....
... EPICENTREs patented MasterAmp™ 10X PCR ... performance and allows improved sensitivity and ... templates. Using MasterAmp™ PCR Enhancer in ... of DNA melting, increases enzyme?s thermal ...
... simple three step procedure (PCR, Exonuclease III ... in one day. The typical cloning efficiency ... , Features and Benefits: , , Universal ... any expression vector , High Cloning Efficiency ...
Biology Products: